Compound Physician required WADA prohibited

Sermorelin

GHRH analog with the cleanest regulatory history of any secretagogue — pulsatile GH release, modern human data is thin.

Compoundable Verified 27 August 2026

The story

Sermorelin's origin story is the rare case where the hypothalamic hormone was found by not looking in the hypothalamus. Through the 1970s, growth hormone-releasing factor was the last of the classical hypothalamic releasing hormones to resist isolation — Roger Guillemin and Andrew Schally had each taken a quarter share of the 1977 Nobel Prize in Physiology or Medicine "for their discoveries concerning the peptide hormone production of the brain" — the remaining half went to Rosalyn Yalow for radioimmunoassay (Nobel Prize 1977, Physiology or Medicine) — but GRF stayed out of reach because hypothalamic tissue contains vanishingly little of it. The breakthrough came from a tumour.

In 1982, Michael Thorner's group at the University of Virginia published the case of a 21-year-old woman with Turner's syndrome who presented with acromegaly. Transsphenoidal surgery found not a discrete pituitary adenoma but diffuse somatotroph hyperplasia, and she stayed acromegalic afterwards. A CT scan located a 5-cm tumour in the tail of her pancreas; when it was removed, her serum GH fell from 70 to 3 ng/mL within two hours and her somatomedin C normalised within six weeks. Extracts of the tumour contained a peptide with GRF activity (J Clin Invest 1982, PMID 6290540). Tumours like hers gave endocrinology what hypothalami could not: gram-scale starting material.

Two groups at the Salk Institute solved it within months of each other in 1982. Jean Rivier, Joachim Spiess and Wylie Vale — working with Thorner's tumour material — characterised the peptide in Nature and established its 39-residue N-terminal sequence by Edman degradation (Nature 1982; Biochemistry 1982, PMID 6295453). Roger Guillemin's group — Brazeau, Ling, Böhlen, Esch and Ying — showed that native tumour-derived GRF, hypothalamic GRF and synthetic replicates were indistinguishable secretagogues of pituitary GH in vitro, with a median effective dose around 15 pM and an effect measurable within 30 seconds (PNAS 1982). Native human GHRH turned out to be 44 amino acids.

Sermorelin is the first 29 of those 44, amidated at the C-terminus. Truncation work at Tulane by David Coy's group produced hpGRF(1-29)-NH2 and a series of substituted "super-active" analogues, establishing the 1-29 amide as the practical parent scaffold (Biochem Biophys Res Commun 1984, PMID 6231028). The decisive human comparison came the same year from Ashley Grossman and colleagues, who reported that GHRH(1-29)NH2 was equipotent to GHRH(1-40) in normal subjects — and, importantly, that of 20 children and young adults classified as GH-deficient by conventional criteria, eight had normal or near-normal GH responses to GHRH, meaning their defect was hypothalamic rather than pituitary (Clin Endocrinol 1984, PMID 6236914). That observation is the entire clinical rationale for the drug: if the pituitary works and the signal upstream is missing, replace the signal.

Serono developed it as Geref. FDA approved NDA 019863 — Geref (sermorelin acetate) injection at an approved product strength of 0.05 mg base/ampoule — a regulatory formulation record, the presentation named in the approval rather than an administered dose — indicated "for evaluating the ability of the somatotroph of the pituitary gland to secrete growth hormone" — on 28 December 1990. NDA 020443 — Geref, at approved product strengths of 0.5 mg and 1.0 mg base/vial (again the presentations recorded in the approval, not doses), indicated for the treatment of idiopathic growth hormone deficiency in children with growth failure — followed on 26 September 1997 (Federal Register, 2013-03-04; Drugs@FDA). The pivotal therapeutic evidence was a 110-child multicentre open-label trial run by the Geref International Study Group (JCEM 1996, PMID 8772599).

The commercial ending was undramatic. EMD Serono notified FDA on 11 July 2008 that the diagnostic ampoule was being discontinued and on 2 December 2008 that the therapeutic vials were; FDA withdrew approval of both NDAs effective 18 June 2009. In 2013, responding to a citizen petition from Alvin J. Lorman (Docket FDA-2012-P-1071) and acting on its own initiative for the diagnostic product, FDA determined that neither product was withdrawn from sale for reasons of safety or effectiveness, having "independently evaluated relevant literature and data for possible postmarketing adverse events for both GEREF products" (Federal Register, 2013-03-04). That finding is why sermorelin's status differs sharply from the rest of this batch.

The route into longevity practice ran through geriatrics rather than bodybuilding forums. Two small studies in the 1990s — Corpas and colleagues giving GHRH(1-29) twice daily to old men, and Vittone and colleagues giving nightly injections to men aged 64-76 — suggested that GH and IGF-1 in older men could be pushed back toward youthful levels by a releasing hormone rather than by GH itself (PMID 1379256; PMID 9005976). After Geref left the market, compounding pharmacies and age-management clinics kept sermorelin in circulation, and by 2026 a narrative review in Frontiers in Endocrinology listed sermorelin first among the GHRH analogues clinicians encounter in "online self-administration protocols" (DOI 10.3389/fendo.2026.1822475).

  1. 1982 Thorner's group cures acromegaly in a 21-year-old woman by removing a GRF-secreting pancreatic islet tumour; pituitary shows somatotroph hyperplasia, not adenoma
  2. 1982 Rivier, Spiess, Thorner and Vale characterise and sequence human pancreatic GRF; Guillemin's group demonstrates equivalence of tumour-derived, hypothalamic and synthetic GRF in vitro
  3. 1984 Coy's group at Tulane synthesises hpGRF(1-29)-NH2 and superactive analogues, fixing the 1-29 amide as the working scaffold
  4. 1984 Grossman et al. show GHRH(1-29)NH2 is equipotent to GHRH(1-40) in humans, and that a substantial minority of "GH-deficient" children have hypothalamic rather than pituitary defects
  5. 1990-12-28 FDA approves NDA 019863 — Geref (sermorelin acetate), approved presentation 0.05 mg base/amp (regulatory formulation record, not a dose), as a pituitary somatotroph function test
  6. 1992 Corpas et al. report GHRH(1-29) twice daily restoring GH and IGF-1 in old men (n=10) — the founding adult-use citation
  7. 1993 Chen et al. randomise 60 children with hypothalamic GHD to GHRH(1-29) or GH: height velocity 9.2-9.3 vs 14.6 cm/yr favouring GH
  8. 1996 Geref International Study Group publishes the pivotal 110-child trial: mean height velocity 4.1 to 7.2 cm/yr at 12 months
  9. 1997-09-26 FDA approves NDA 020443 — Geref, approved presentations 0.5 mg and 1.0 mg base/vial (regulatory formulation record, not a dose), for idiopathic GHD in children with growth failure
  10. 2008 EMD Serono notifies FDA of discontinuation: diagnostic ampoule 11 July 2008, therapeutic vials 2 December 2008
  11. 2009-06-18 FDA withdraws approval of NDA 019863 and NDA 020443 (74 FR 23407)
  12. 2013-03-04 FDA determines both Geref products were not withdrawn for reasons of safety or effectiveness, keeping the ANDA pathway open
  13. 2023-09 FDA places 20 peptide bulk substances — including ipamorelin, CJC-1295, thymosin alpha-1, kisspeptin-10, epitalon and BPC-157 — in Category 2 of the interim bulks lists. Sermorelin is not among them
  14. 2026-07-23/24 FDA Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-C, emideltide, semax and epitalon for the 503A bulks list. Sermorelin was not on the agenda, and no FDA document cited in this file schedules any further review of GHRH analogues

What it does

A GHRH analog with the cleanest regulatory history of any secretagogue — previously FDA-approved, withdrawn for commercial rather than safety reasons. Stimulates pulsatile GH release; modern longevity-use data is thin.

A GHRH analog, shorter-acting than tesamorelin. It stimulates pulsatile pituitary GH release rather than a sustained spike — the basis for its lower-risk profile relative to exogenous GH.

  • growth hormone (pulsatile release)
  • IGF-1

What the evidence shows

Sermorelin is the one compound in this batch that was actually an approved US drug, and its approvals ended for commercial reasons rather than safety ones — a finding this file establishes from primary regulator documents: Geref Diagnostic (NDA 019863) approved 1990-12-28, Geref (NDA 020443) approved 1997-09-26, both NDAs withdrawn effective 2009-06-18 (74 FR 23407), and FDA determining in 2013 (78 FR 14095) that it found neither product withdrawn for reasons of safety or effectiveness. That history leaves behind a registration-grade human dataset: a 110-child pivotal trial, the only randomised comparison against recombinant growth hormone, and a validated diagnostic-testing literature. The limitation is population and endpoint rather than data quality — essentially every controlled study was in GH-deficient children or in diagnostic bolus testing, and the adult record is two small, short, uncontrolled studies in older men (n=10 and n=11), the longer of which, at six weeks, found that IGF-1 did not move at all. IGF-1 is also where the adult evidence contradicts itself: Corpas reports a rise on twice-daily dosing, Vittone none on once-nightly, and it is the marker adult monitoring depends on. No trial in any jurisdiction has enrolled healthy or sub-clinically deficient adults for a body-composition, sleep, recovery or longevity endpoint, so the adult-wellness use that now dominates rests on those two studies and on extrapolation from a pediatric label.

Overall evidence strength: Low certainty

  • Geref International Study Group — Thorner M, Rochiccioli P, Colle M, Lanes R, et al. (1996) — the pivotal therapeutic trial (1996) Case series (uncontrolled)

    Children growing 4.1 cm/year grew 8.0 cm/year at six months and 7.2 cm/year at twelve, with no adverse biochemical changes, no fasting-glucose change and no excessive IGF-1 generation — but there was no control group, and roughly a quarter were not classed as good responders even at six months.

    Source PMID 8772599

  • Chen RG, Shen YN, Yei J, Wang CF, et al. (1993) — the only randomised comparison against recombinant GH (1993) Randomized controlled trial

    Even in the children best suited to it, sermorelin produced about 9.2-9.3 cm/year against 14.6 cm/year for growth hormone itself, and the authors concluded GHRH "is unlikely to be as effective as GH for the promotion of growth." Every child on the high dose and 19 of 20 on the low dose developed anti-GHRH antibodies, which had almost disappeared nine months after stopping; IGF-1 rose and then drifted back to pre-treatment values.

    Source PMID 8329830

  • Corpas E, Harman SM, Piñeyro MA, Roberson R, et al. (1992) — the founding older-adult study (1992) Randomized controlled trial

    Two weeks of twice-daily injections at the higher dose brought older men's 24-hour GH output and IGF-1 to levels statistically indistinguishable from young men's, with no change in fasting glucose, blood pressure or routine chemistry — the most-cited evidence behind adult use, and it lasted fourteen days and measured no clinical outcome. A second finding is routinely omitted: GH responses to an intravenous GHRH test did not differ between young and old men, before or during treatment.

    Source PMID 1379256

  • Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, et al. (1997) — the older-adult study that measured outcomes (1997) Case series (uncontrolled)

    Six weeks of nightly injections raised nocturnal GH release and peak amplitude — and changed essentially nothing else. IGF-1, IGFBP-3, GHBP, weight, BMI, waist-to-hip ratio, DEXA muscle and fat, muscle histology, glucose, insulin and lipids were all unchanged; two of six strength measures and one endurance measure improved. The authors concluded that "single nightly doses of GHRH are less effective than multiple daily doses in eliciting GH- and/or IGF-I-mediated effects."

    Source PMID 9005976

  • Biller BMK, Samuels MH, Zagar A, Cook DM, et al. (2002) — the diagnostic-use validation (2002)

    The arginine + GHRH test matched the insulin tolerance test for accuracy — 95% sensitivity and 91% specificity at a peak-GH cut-point of 4.1 µg/L versus 96% and 92% for the ITT — and patients preferred it, which is why a GHRH product had standalone value in endocrine practice.

    Source PMID 11994342

  • Saenger P, Pescovitz OH, Bercu BB, Murray FT, et al. (2001) — what happened to the non-responders (2001) Case series (uncontrolled)

    Children who did not grow adequately on sermorelin grew well on growth hormone, and the size of their GH response predicted it — establishing both that sermorelin non-response is common and that it is not a dead end. It also documents injection-site reaction as a real, if uncommon, reason for stopping.

    Source PMID 11572326

  • Supporting: Garcia JM et al. (2013) — the withdrawal, recorded in the primary literature (2013)

    A multicentre validation study of oral macimorelin was designed to compare it against arginine + GHRH; after 43 patients and 10 controls had been tested, "the GHRH analog Geref Diagnostic [GHRH(1-29)NH2] became unavailable in the United States," and the trial was finished with macimorelin alone — the cleanest primary-source record of what the withdrawal cost clinically. DOI 10.1210/jc.2013-1157 · PMID 23559086.

    Source PMID 23559086

What studies used — not a recommendation.

  • Prepubertal GH-deficient children, previously untreated (n=110) — the pivotal trial for the approved pediatric indication. Lawful US channel existed 1997-2009 under NDA 020443; none exists now · 30 µg/kg/day, subcutaneous, once daily at bedtime · Up to 12 months PMID 8772599
  • Children with GH deficiency of hypothalamic origin (n=60, randomised against recombinant GH) — approved pediatric indication. Channel as above · 30 or 60 µg/kg/day, versus recombinant GH 0.1 IU/kg/day · 6 months PMID 8329830
  • Prepubertal GH-deficient children (n=16) — approved pediatric indication; the longest human exposure published. Channel as above · 30 µg/kg/day, subcutaneous, once daily · 12-24 months PMID 7735367
  • Children with radiation-induced GH deficiency (n=9) — a GH-deficiency subgroup; whether the 1997 label's "idiopathic" wording reached acquired deficiency is not established in any source we hold. Channel uncertain even in the approved era · 15 µg/kg twice daily, subcutaneous · 1 year, then 1 year of GH PMID 9231053
  • Prepubertal children with idiopathic short stature or GH neurosecretory dysfunction (n=17) — outside the approved indication; investigational, no lawful supervised channel · 30 µg/kg once nightly, subcutaneous · 6 months, followed 12 months PMID 10905389
  • Healthy non-obese men aged ~68 (n=10), with 9 young men as reference — adult GH optimisation. Never an approved indication in any jurisdiction; no lawful supervised US channel has ever existed for this population · 0.5 mg and 1 mg per injection, subcutaneous, twice daily; doses given in randomised order with a 14-day washout · 14 days per dose PMID 1379256
  • Healthy men aged 64-76 with low baseline IGF-1 (n=11) — adult GH optimisation. No approved indication, no lawful supervised US channel. This is the closest published analogue to real-world adult use, and it is 11 uncontrolled subjects for six weeks · 2 mg per injection, subcutaneous, once nightly, self-administered at home · 6 weeks PMID 9005976
  • Diagnostic testing of somatotroph capacity, adults and children — the approved diagnostic indication. Lawful US channel existed 1990-2009 under NDA 019863; no marketed product now · 1 µg/kg as a single intravenous bolus, with GH sampled over 60-120 minutes; in the combined test, given with L-arginine · Single administration PMID 6236914
  • Short-statured children under diagnostic investigation who had not responded to a single GHRH bolus ("priming", n=16) — diagnostic setting, but a repeat-dose protocol the single-bolus label did not describe. Investigational within the diagnostic indication · 5 µg/kg subcutaneously on six consecutive days before repeat IV testing · 6 days PMID 7735368
  • Approved US labelling — pediatric idiopathic GHD with growth failure (Geref, 0.5 and 1.0 mg base/vial) and evaluation of somatotroph capacity to secrete GH (Geref Diagnostic, 0.05 mg base/amp). Both withdrawn effective 2009-06-18 · The label text is not retrievable — Drugs@FDA states "Label is not available on this site," so no label figures are reproduced · n/a

Common misconceptions

“Sermorelin is a safer, more natural alternative to HGH — it works with your own pituitary, so you can't overdose. Negative feedback protects you.”

This is the load-bearing claim of the sermorelin market, and it is stated in almost those words. One clinic page tells prospective patients that "the pituitary cannot produce GH beyond its physiological capacity regardless of Sermorelin dose," that "pituitary regulation prevents supraphysiological GH levels — reducing the side effect risk," and that "this self-limiting mechanism is the key safety advantage of Sermorelin over direct HGH" (a clinic marketing page, de-named under the "never name a vendor" rule; cited as evidence of what is claimed, not of what is true — the URL is held in the internal verification note in the editorial block). What is documented, and true. Sermorelin acts upstream: it is a GHRH-receptor agonist on the somatotroph, so the GH released is the body's own, comes in pulses, and is opposed by somatostatin and GH/IGF-1 feedback in a way injected recombinant GH is not. The trial record bears out the practical consequence — the pivotal 110-child study reported "no change in fasting glucose concentration or excessive generation of insulin-like growth factor I" over a year, and a 20-child US trial reported the same (PMID 8772599; PMID 1400880). That is the honest core of the claim. What is extrapolation. Three findings break the stronger version. Sustained GHRH drive demonstrably does override the feedback loop in humans. The molecule exists because a 21-year-old woman's pancreatic tumour secreted GHRH continuously and gave her full acromegaly with diffuse somatotroph hyperplasia; removing it dropped her GH from 70 to 3 ng/mL in two hours (PMID 6290540). A 2021 review counted 47 published cases of acromegaly from ectopic GHRH-secreting tumours, with pituitary hyperplasia and, in its index case, progression to a somatotropinoma (DOI 10.20945/2359-3997000000395). This does not show that injected sermorelin causes acromegaly — pulsatile dosing of a short-acting peptide is not a tumour secreting continuously for years — but it refutes the general principle. "The pituitary cannot exceed its physiological capacity regardless of GHRH" is not a law of endocrinology; it is a statement about one studied exposure pattern. What the loop actually does under repeated dosing is blunt the drug. Six children on continuous subcutaneous infusion for six months showed a biphasic response: 24-hour integrated GH rose from 1.6 to 3.5 µg/L/min, then fell to 1.9 by six months, with one child in complete GH suppression and two showing a single daily peak above 5 µg/L (PMID 8329829). Eight children on thrice-daily intranasal dosing had peak amplitudes "variably reduced after 6 weeks… and further reduced at 6 months" (PMID 8329828). Anti-GHRH antibodies are common: 20/20 high-dose and 19/20 low-dose children in the randomised comparison (PMID 8329830), 4/11 then 6/11 in another cohort (PMID 7735367). The self-limiting mechanism is real, and it limits the effect at least as reliably as it limits the risk. In the population that buys it, IGF-1 often does not move. Six weeks of nightly injections in men aged 64-76 raised nocturnal GH release but left IGF-1, IGFBP-3, GHBP, DEXA body composition, muscle histology, glucose, insulin and lipids unchanged (PMID 9005976). And what happens to GHRH responsiveness with age? Less than the pitch implies. Corpas et al. found peak and integrated GH responses to an intravenous GHRH test "did not differ between young and old men either before or during GHRH treatment" — the aged pituitary answered a GHRH signal about as well as a young one; what had fallen was spontaneous secretion (PMID 1379256). In 200 healthy controls given the GHRH-arginine test, BMI accounted for 21% of the variability in peak GH, sex for 20%, and age for only 5% (DOI 10.1530/EJE-16-0668). The premise that the older pituitary needs a nudge is partly right — hypothalamic signalling does decline — but body composition determines the size of the response far more than age does. Honest answer: the claim is directionally reasonable and stated far too strongly. Sermorelin is genuinely harder to push into supraphysiological GH than injected GH is, and a year of pediatric dosing moved neither glucose nor IGF-1 abnormally. But no study has tested a safety ceiling in adults, the longest adult exposure on record is six weeks, sustained GHRH excess is the documented cause of a form of acromegaly, and the best-documented consequence of repeated dosing is tachyphylaxis. Anyone saying the mechanism makes dose irrelevant is asserting something untested.

“Sermorelin isn't FDA-approved" / "The FDA banned it.”

both are wrong, in opposite directions. Sermorelin acetate was approved twice — NDA 019863 (Geref Diagnostic) on 28 December 1990 and NDA 020443 (Geref, for idiopathic GHD in children with growth failure) on 26 September 1997. EMD Serono notified FDA of discontinuation in July and December 2008; FDA withdrew both approvals effective 18 June 2009. In 2013 FDA formally determined that neither product was withdrawn from sale for reasons of safety or effectiveness, having "independently evaluated relevant literature and data for possible postmarketing adverse events for both GEREF products" — a determination that keeps the generic pathway open (Federal Register, 2013-03-04). No FDA-approved sermorelin product is marketed today, so "it is FDA-approved" is also false in the present tense. The accurate sentence: it was approved, it was withdrawn commercially, and FDA said so in writing.

“Sermorelin works as well as growth hormone, without the downside.”

in the only randomised head-to-head it did not — height velocities of 9.2 and 9.3 cm/yr on GHRH(1-29) against 14.6 cm/yr on GH, in the population most favourable to a releasing hormone, with the authors concluding GHRH "is unlikely to be as effective as GH" (PMID 8329830). About a quarter of children in the pivotal trial were not good responders (PMID 8772599); 31% were switched to GH in another cohort (PMID 7735367); and children who failed sermorelin grew well on GH afterwards (PMID 11572326). Sermorelin's advantage was never potency — it was pulsatility, tolerability, and working only where the pituitary still can.

“Oral, sublingual and nasal sermorelin work — it's the same molecule.”

GRF(1-29)NH2 is cleaved by dipeptidyl peptidase IV in plasma to the inactive GRF(3-29)NH2, and by the same enzyme at the intestinal brush border — which is precisely why DPP-IV-resistant analogues were designed (PMID 8583376). No human study has established oral bioavailability. The only published non-injected human data is intranasal, given three times daily at roughly fifty times the weight-based diagnostic IV bolus, with peak amplitudes falling by six weeks, three of eight children developing anti-GHRH antibodies, and no increase in six-month stadiometric height velocity (PMID 8329828). Every trial that produced a positive growth result used subcutaneous injection.

“Sermorelin and CJC-1295 are basically the same thing.”

they share a backbone and little else. Both are built on GHRH(1-29), but CJC-1295 carries substitutions plus (in the DAC form) an albumin-binding linker that converts a duration of action measured in minutes into one measured in days; WADA names them separately for that reason (2026 Prohibited List, S2.2.4; DOI 10.3389/fendo.2026.1822475). The distinction matters for exactly the reason gives: sermorelin's short action is what keeps release pulsatile. CJC-1295 also sits in FDA's Category 2 bulks list where sermorelin does not, and ECRI and ISMP record that a Phase 2 CJC-1295 trial in HIV-lipodystrophy "was halted after a participant's death from a fatal cardiac event" (ECRI/ISMP, 2026).

“Compounded sermorelin is the same as the drug that was approved.”

nothing establishes that. Analytical testing of gray-market peptide products found purity from 5% to 75% across ten products, with arsenic and lead up to ten times the ICH Q3D parenteral limit, and FDA laboratory data presented at the December 2024 PCAC meeting showed differences in innate immune activation between commercial and compounded peptide API lots (ECRI/ISMP, 2026). Those figures describe the compounded and gray peptide market generally; we have not found them attributed to sermorelin specifically and do not attribute them to it here. What is specific to sermorelin is that anti-GHRH antibodies were common even with pharmaceutical-grade product (PMID 8329830), which makes peptide-related impurities a non-theoretical concern for this molecule. ---

Who it's for, who should skip

Only under physician supervision. Status is compoundable — available via 503A compounding; the prior approval was withdrawn for commercial, not safety, reasons. Modern data in healthy adults is thin. Not for anyone with active or recent cancer, or who is pregnant.

Skip it if

  • active or recent cancer — GH-axis stimulation can accelerate tumor growth. hard block
  • pregnancy — Contraindicated in pregnancy. hard block

Running it

Form
injectable
Dose
nightly subcutaneous (historical, to mimic GH pulsatility)
Titration
no standardized longevity protocol; physician-directed

What to expect

  • Acute (minutes) — A single dose releases GH within minutes — in vitro, GRF stimulated GH release in under 30 seconds at a median effective dose ~15 pM; the diagnostic test samples GH over 60-120 minutes (Confidence: Trial-documented (DOI 10.1073/pnas.79.24.7909; PMID 11994342))
  • Days 1-14 (adults) — Twice-daily injection at the higher of two doses raised 24-hour GH output and IGF-1 in older men to levels indistinguishable from young men's; the lower dose did not reach significance (Confidence: Trial-documented, uncontrolled, n=10 (PMID 1379256))
  • Weeks 1-6 (adults) — Nightly injection raised nocturnal GH release and peak amplitude but left IGF-1, IGFBP-3, DEXA body composition, muscle histology, glucose, insulin and lipids unchanged; 2 of 6 strength measures improved (Confidence: Trial-documented, uncontrolled, n=11 (PMID 9005976))
  • Months 1-6 (children) — Height velocity roughly doubled — 4.1 to 8.0 cm/yr; ~74% classed as good responders, so about a quarter were not (Confidence: Trial-documented, uncontrolled (PMID 8772599))
  • Plateau / attenuation — 12-month height velocity (7.2 cm/yr) was below the 6-month figure (8.0). Under continuous infusion, 24-hour integrated GH rose then fell below baseline by six months; under thrice-daily intranasal dosing, peak amplitudes fell by six weeks and further by six months (Confidence: Trial-documented (PMID 8772599; PMID 8329829; PMID 8329828))
  • Anti-drug antibodies — Near-universal in the randomised comparison; 4/11 at six months and 6/11 at twelve in another cohort. No correlation with growth in either (Confidence: Trial-documented (PMID 8329830; PMID 7735367))
  • Post-cessation — Anti-GHRH antibodies "had almost disappeared by 9 months after stopping treatment." Nothing else documented — no adult study has measured GH, IGF-1, sleep or body composition after stopping (Confidence: Antibodies: trial-documented. Everything else: no data (PMID 8329830))
  • Long-term (>24 months) — No published human exposure exceeds 24 months in any population (Confidence: No data (PMID 7735367))
  • Claimed adult timelines ("energy and sleep in 2-4 weeks, body composition by 3-6 months") — Circulate throughout clinic and telehealth marketing; no controlled study supports any of them, and the only adult DEXA measurement found no change at six weeks (Confidence: Anecdotal, low confidence (PMID 9005976))

Response signs

Likely working

  • Measurable rise in nocturnal GH on overnight sampling — Trial-documented, uncontrolled, older men · PMID 9005976 Trial-documented
  • In a GH-deficient child, growth velocity rising more than 2 cm/yr over baseline — the explicit responder definition used in the trials — Trial-documented · PMID 7735367 Trial-documented
  • Improved strength on some but not all lifts — Trial-reported, uncontrolled — 2 of 6 measures, n=11, unblinded · PMID 9005976 Trial-reported
  • Deeper or more restorative sleep — Anecdotal, low confidence — the most common subjective claim in clinic marketing; no trial has measured sleep on sermorelin · A clinic marketing page, de-named under the "never name a vendor" rule (claim only); URL in the internal verification note Anecdotal
  • Visible change in body composition — Anecdotal, low confidence — contradicted by the only DEXA measurement in the literature · PMID 9005976 Anecdotal

Adverse — seek review

  • Injection-site reaction, particularly one severe enough to interfere with continuing — Trial-documented — mild irritation in 3 patients in the randomised trial; one child in a 27-child follow-up had withdrawn specifically for injection-site reactions · PMID 8329830; PMID 11572326 Trial-documented
  • A clear early response that fades over weeks to months — Trial-documented as tachyphylaxis — and the point at which anti-GHRH antibodies become the relevant test · PMID 8329829 Trial-documented
  • Swelling or oedema, new joint pain, hand numbness or tingling — Class inference from GH excess, listed by USADA for sermorelin; not reported in any sermorelin trial · USADA Inference
  • New or worsening glucose dysregulation, especially alongside insulin — Class-level inference, explicitly not documented for sermorelin · ECRI/ISMP, 2026 Class-level
  • Any systemic reaction — fever, rash, malaise — after a dose from a non-pharmacy product — Inference from documented gray-market purity and contamination findings, not from sermorelin pharmacology · ECRI/ISMP, 2026 Inference

Common / neutral

  • Facial flushing or warmth shortly after a dose — Trial-adjacent — a recognised acute effect of GHRH in the diagnostic-testing literature; not quantified in the therapeutic trials · PMID 11994342
  • No perceptible effect at all — Consistent with the record: in the best-measured adult study most objective endpoints did not move · PMID 9005976
  • Transient rise in serum phosphate on routine chemistry — Trial-documented, n=10 — a marker of GH action rather than a problem · PMID 1379256 Trial-documented

Getting it right

  • Monitoring: Establish a pre-exposure baseline. The trials that measured anything measured it before and after: fasting glucose and insulin, IGF-1, general chemistry and haematology (PMID 8772599; PMID 1379256). mitigate side effect
  • Monitoring: Do not assume IGF-1 is a working efficacy marker in adults. records a direct conflict between the two adult studies. A flat IGF-1 is consistent with the published record and does not by itself mean a product is inert or a person is a non-responder. mitigate side effect
  • Monitoring: Loss of response is the documented failure mode, not runaway effect. Declining GH response over weeks to months is the best-characterised longitudinal finding (PMID 8329829), and anti-GHRH antibodies are the mechanism with a measurable correlate (PMID 8329830). mitigate side effect
  • Monitoring: Time-box the question. No published human exposure exceeds 24 months in any population and none exceeds six weeks in adults; open-ended adult use sits outside the observed window of every study conducted. mitigate side effect
  • Monitoring: Diagnosis before treatment. The logic of a GHRH analogue is that the pituitary works and the hypothalamic signal does not; establishing that requires provocative testing, and the arginine + GHRH and ITT protocols have published cut-points (PMID 11994342). Non-response was common and predictable from GH testing (PMID 11572326). mitigate side effect
  • General safety: What the trials documented, described as trials documented it. Every positive human result used subcutaneous injection, and the pivotal pediatric trial gave a single daily dose at bedtime, aligning with the physiological nocturnal GH pulse (PMID 8772599). Frequency mattered counter-intuitively: the more frequent regimen produced IGF-1 changes and the once-nightly one did not (PMID 1379256; PMID 9005976), while continuous exposure produced suppression rather than amplification (PMID 8329829). This is what was observed, not a schedule to follow. mitigate side effect
  • General safety: Product provenance dominates. USADA identifies three routes — compounding pharmacies with a prescription, anti-aging and wellness clinics, and unregulated online sellers — and warns that unregulated sources "may provide contaminated or mislabeled products" (USADA). ECRI and ISMP's purity and heavy-metal findings apply to the gray peptide market broadly, not to sermorelin specifically. mitigate side effect
  • General safety: Immunogenicity is a specific, not generic, concern here. Anti-GHRH antibodies were near-universal in the approved-era trials using pharmaceutical-grade product (PMID 8329830), so FDA's concern about peptide-related impurities driving immunogenicity is not abstract for this molecule (ECRI/ISMP, 2026). mitigate side effect
  • General safety: Combination use removes attributability, and ipamorelin — sermorelin's most common partner — carries safety signals sermorelin does not. mitigate side effect
  • General safety: Athletes and service members face strict liability. See. mitigate side effect
  • The physician conversation: Has GH deficiency actually been established, and by which test and cut-point? (A single low IGF-1 does not establish it.) mitigate side effect
  • The physician conversation: If the problem is the pituitary rather than the hypothalamus, why would a releasing hormone be expected to work at all? (.) mitigate side effect
  • The physician conversation: What is being tracked, how often, and what result would mean this is not working? (— and IGF-1 may not move.) mitigate side effect
  • The physician conversation: What is the plan if response fades at six to twelve weeks? (.) mitigate side effect
  • The physician conversation: Where is the product made, and what independent testing exists for that specific lot? mitigate side effect
  • The physician conversation: What else is being taken, including anything from a non-pharmacy source? (.) mitigate side effect
  • The physician conversation: Is there any competitive sport, collegiate or military testing obligation? (— prohibited at all times.) mitigate side effect
  • The physician conversation: Is there a personal or family history of cancer, diabetes or untreated pituitary disease that changes the risk calculus? mitigate side effect

Measuring it

Retest IGF-1 — Baseline, then on a clinician-set schedule — no guideline sets an IGF-1 interval for this agent, and the rhGH cadence is not borrowed..

  • IGF-1 baseline
  • IGF-1 on cycle
  • Fasting glucose baseline
  • Fasting glucose on cycle
  • HbA1c baseline
  • HbA1c quarterly

How biomarkers respond

  • Fasting glucose May deteriorate — No change documented — 110 children over a year, 20 children over a year, 11 older men over six weeks. Genuine reassurance within those windows and populations; not evidence about longer adult exposure — Trial-documented negative, sermorelin-specific (PMID 8772599; PMID 1400880; PMID 9005976) Trial-documented

Safety

  • injection-site reactions, flushing

Stacking & alternatives

Access & cost

Prescription or clinician order — typically via peptide-therapy physician (503A compounding).

A lawful channel plausibly exists, but there is no price to report from it — and that is the finding. No FDA-approved sermorelin product is marketed in the United States, so there is no list price, no average wholesale price and no reference product in commerce; both Geref NDAs sit in the Orange Book's Discontinued Drug Product List (Federal Register, 2013). FDA's 2013 determination that neither product was withdrawn for safety or effectiveness reasons is the finding that leaves the ANDA pathway available (Federal Register, 2013); no ANDA has been approved. What would follow from one is not forecast here, and no source forecasts it. What exists instead is compounded product dispensed on prescription and priced independently by each pharmacy and telehealth practice. USADA documents the channel structure plainly: sermorelin reaches users through compounding pharmacies with a prescription, anti-aging and wellness clinics, and unregulated online and black-market websites (USADA). We deliberately did not price from seller or telehealth pages — a figure scraped from a marketing page is not a sourced market price. The one documentable economic fact is structural: NDA 020443 carried orphan designation, and the sponsor discontinued it commercially rather than for any safety or efficacy reason (Drugs@FDA NDA 020443). (No INTERNAL subsection: no journalist-reported gray-market figure specific to sermorelin was found. If Klik wants market-sizing numbers here, they need sourcing first.) ---

Questions

Does sermorelin actually work?
For its approved purpose — accelerating growth in GH-deficient children with an intact pituitary — yes, with registration-grade evidence: 110 children roughly doubled their height velocity (PMID 8772599). For the adult purposes it is now sold for, the evidence does not exist. The two published adult studies ran 14 days (n=10) and six weeks (n=11), and the six-week study found no change in body composition, IGF-1, glucose or lipids (PMID 1379256; PMID 9005976).
Is sermorelin FDA-approved?
It was, twice — as a diagnostic agent in 1990 and for pediatric GH deficiency in 1997 — and both approvals were withdrawn effective 18 June 2009 after the manufacturer discontinued the products. FDA determined in 2013 that neither was withdrawn for safety or effectiveness reasons. No FDA-approved sermorelin product is marketed today (Federal Register, 2013).
How long does sermorelin take to work?
Depends what "work" means. GH release is immediate — minutes (DOI 10.1073/pnas.79.24.7909). Growth in deficient children was measurable at three to six months (PMID 8772599). For the adult outcomes people want — sleep, recovery, body composition — no trial has established a timeline, and the six-week adult study measured DEXA body composition and found no change (PMID 9005976).
Is sermorelin safer than HGH?
Different, and far less characterised in adults. Its mechanism preserves pulsatile release, and pediatric trials over a year found no change in fasting glucose and no excessive IGF-1 generation (PMID 8772599; PMID 1400880). But USADA lists swelling and oedema, joint and nerve pain, insulin resistance and diabetes risk, hypertension, cardiac hypertrophy and cardiomyopathy among the concerns, and warns that unregulated sources "may provide contaminated or mislabeled products" (USADA). See.
Oral, sublingual or nasal vs. injectable — does the non-injected form work?
Only the injected form has ever produced a positive growth result. Sermorelin is cleaved by dipeptidyl peptidase IV in plasma and at the intestinal brush border to an inactive fragment, which is why oral delivery is mechanistically implausible and why DPP-IV-resistant analogues were designed (PMID 8583376). The only published non-injected human data is intranasal, at fifty times the diagnostic IV dose, and six-month height velocity did not increase (PMID 8329828). Oral and sublingual claims have no human bioavailability data behind them.
Does sermorelin cause weight loss?
No human trial has reported it. The only adult study to measure body composition properly — DEXA plus weight, BMI and waist-to-hip ratio over six weeks — found no change in any of them (PMID 9005976). Weight-loss claims are extrapolated from what growth hormone does at pharmacological doses.
What happens when you stop?
Almost nothing has been documented. The one measured post-cessation finding is that anti-GHRH antibodies largely disappeared within nine months (PMID 8329830). No study has followed adults after discontinuation. Because sermorelin acts on the pituitary rather than replacing GH, there is no documented equivalent of post-hormone suppression — but "not documented" is not "does not happen."
Will it show up on a drug test?
Methods exist. Whether they catch anyone is a separate question, and the published record does not answer it. Sermorelin is a named target in validated urine methods using cation-exchange SPE with UHPLC-MS/MS and nano-LC-Orbitrap MS (PMID 37806509; PMID 41138283). A 2021 review reported that although there is evidence of GHRH-analogue use "based on admissions and intelligence, they do not appear to have been found in anti-doping samples by WADA accredited laboratories" (DOI 10.1002/dta.3183). No source states that the gap between the two has narrowed. Reading the later method papers as evidence that detection is improving on the 2021 position would be this dossier's own inference joining three unrelated papers, and it is not asserted here. It is prohibited regardless. ---

Last reviewed 27 August 2026. Regulatory status verified 27 August 2026.